Institute for Cancer Research
Institute for Cancer Research has since its foundation in 1954 played a central role within the field of cancer research both in Norway and internationally. The Institute has seven research departments and more than 320 employees, master students included. About 70% of the employees and projects are externally funded.
The Institute has internationally strong research groups within biochemistry, cell and tumor biology, genetics, radiation biology, immunology and cancer prevention. For more than 30 years there has been a close interaction between researchers at the Institute and cancer surgeons, oncologists and pathologists. This emphasis on translational science has resulted in numerous clinical protocols based on in-house research, and the Institute is a key partner in the Comprehensive Cancer Center, organizationally under the Division of Surgery and Cancer Treatment at Oslo University Hospital.
Scientific director
Scientific production - Institute for Cancer Research
| Publications | |
| 2012 | so far |
| 2011 | 184 |
| 2010 | 199 |
| 2009 | 167 |
| 2008 | 143 |
Print this page [86994 visits]Latest news
Gordon Research Conference awards to Haugsten and Zakrzewska
Ellen Margrethe Haugsten from Antoni Wiedlocha’s group at the Department of Biochemistry was awarded a prize for her talk - entitled "Clathrin – and dynamin-independent endocytosis of FGFR3 – implication for signaling", at the "Gordon Research Conference: Fibroblast Growth Factors in Development & Disease", held May 13-18, 2012 at Les Diablerets, Switzerland.
Malgorzata Zakrzewska received the price for a poster on "ERK-mediated phosphorylation of FGF receptor 1 on Ser777 confers negative feedback on FGF signaling", with Ellen M. Haugsten, Beata Nadratowska-Weselowska, Angela Oppelt, Yixin Jin, Jacek Otlewski, Jørgen Wesche and Antoni Wiedlocha,
Institute Seminar - Wednesday May 23rd
Giske Ursin
The institute seminar on Wednesday May 23rd will be held by Giske Ursin, Director of the Cancer Registry of Norway.
Title of her talk: How can the Norwegian cancer registry improve our biological understanding of cancer and cancer care?
Time and place: 12.00, Auditorium, new research building, Montebello.
Untangling the development of breast cancer
Researchers announce the first comprehensive genome studies of the evolution of 21 breast cancers
In two back-to-back reports published online on 17 May in Cell (journal impact factor 32.4) , researchers have sequenced the genomes of 21 breast cancers and analysed the mutations that emerged during the tumours‟ development.
Led by researchers from the Wellcome Trust Sanger Institute, the team created a catalogue of all the mutations in the genomes of the 21 cancer genomes and identified the mutational processes that lead to breast cancer. They found that these mutations accumulate in breast cells over many years, initially rather slowly, but picking up more and more momentum as the genetic damage builds up.
Anita Langerød and Anne-Lise Børresen-Dale (photo) from the Department of Genetics at the Institute for Cancer Research have made strong contributions to this work.
Understanding breast cancer
Landscape of cancer genes and mutational processes in breast cancer
In a study recently published in Nature (journal impact factor 36.1), researchers describe nine new genes that drive the development of breast cancer. This takes the tally of all genes associated with breast cancer development to 40.
The team - which includes Anita Langerød and Anne-Lise Børresen-Dale from the Department of Genetics at the Institute for Cancer Research - examined all the genes in the genomes of 100 cases of breast cancer. The mutated cancer-causing genes were different in different cancer samples, indicating that breast cancer is genetically very diverse. Understanding the consequences of this diversity will be important in progressing towards more rational treatment.
Landscape of cancer genes and mutational processes in breast cancer
May 21, 2012
Latest publications
Inst. for Cancer Research
Liposarcoma Cells with Aldefluor and CD133 Activity have a Cancer Stem Cell Potential
Clin Sarcoma Res, 1 (1), 8 (in press)
PubMed 22612877
Mutational Processes Molding the Genomes of 21 Breast Cancers
Cell (in press)
PubMed 22608084
The Life History of 21 Breast Cancers
Cell (in press)
PubMed 22608083
Selected publications
Journal Impact Factor > 5, first or last author from the Institute for Cancer Research
Synthesis of Highly Efficient, Ca-Based, Al(2) O(3) -Stabilized, Carbon Gel-Templated CO(2) Sorbents
Adv Mater (in press)
PubMed 22570251
Proteomic analysis of microvesicles released by the human prostate cancer cell line PC-3
Mol Cell Proteomics (in press)
PubMed 22457534
Efficient siRNA Targeted Delivery into Cancer Cells by Gastrin-Releasing Peptides
Bioconjug Chem (in press)
PubMed 22443209
